ZIA CP010152 - 10104 (ZIA) | |||
---|---|---|---|
Title | PLCO - Special Studies | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Purdue, Mark | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $44,476 | Project Dates | 10/01/2003 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Colon/Rectum (25.0%) Lung (25.0%) Ovarian Cancer (25.0%) Prostate (25.0%) |
||
Research Type | |||
Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors Resources and Infrastructure Related to Etiology |
|||
Abstract | |||
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial is a large randomized trial to determine if screening for these cancers reduces mortality. The Trial is carried out by the NCI under contract with investigators at ten clinical centers in the United States. The study includes approximately 155,000 volunteers (recruited from 1993 through 2001, ages 55-74, equally distributed to the screening and control arms of the Trial). The PLCO Etiology and Early Markers Study (EEMS) supports etiologic and early detection studies of cancers and other conditions. This Study (Cas ID: 10104) supports repository and informatics for EEMS and methods development work to maximize scientific value of the resource. |